Emerald Acquisition Ltd. bought a new stake in shares of Imperva Inc. (NYSE:IMPV) during the second quarter, according to its most recent disclosure with the SEC. The fund bought 86,744 shares of the company’s stock, valued at approximately $3,732,000. Emerald Acquisition Ltd. owned about 0.27% of Imperva as of its most recent SEC filing.

Several other large investors have also made changes to their positions in IMPV. Bank of Montreal Can acquired a new stake in shares of Imperva during the second quarter valued at about $107,000. Wellington Management Group LLP increased its position in Imperva by 2.2% in the first quarter. Wellington Management Group LLP now owns 450,415 shares of the company’s stock valued at $22,745,000 after buying an additional 9,620 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Imperva by 3.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 697,284 shares of the company’s stock valued at $35,213,000 after buying an additional 21,266 shares during the last quarter. JPMorgan Chase & Co. increased its position in Imperva by 46.8% in the first quarter. JPMorgan Chase & Co. now owns 1,479,012 shares of the company’s stock valued at $74,688,000 after buying an additional 471,250 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its position in Imperva by 198.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 54,560 shares of the company’s stock valued at $2,755,000 after buying an additional 36,250 shares during the last quarter. 93.26% of the stock is owned by hedge funds and other institutional investors.

Shares of Imperva Inc. (NYSE:IMPV) traded up 0.51% during trading on Wednesday, reaching $43.00. The company’s stock had a trading volume of 426,950 shares. The stock’s market cap is $1.40 billion. The company has a 50 day moving average of $45.90 and a 200-day moving average of $44.25. Imperva Inc. has a 12-month low of $31.11 and a 12-month high of $77.99.

Imperva (NYSE:IMPV) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.19. The business earned $57.87 million during the quarter, compared to the consensus estimate of $66.06 million. Imperva had a negative return on equity of 25.68% and a negative net margin of 23.75%. The business’s revenue was up 8.2% on a year-over-year basis. During the same period last year, the company earned ($0.08) EPS. Analysts forecast that Imperva Inc. will post ($0.80) EPS for the current year.

Several research analysts have recently weighed in on IMPV shares. Deutsche Bank AG reiterated a “buy” rating and set a $45.00 price target on shares of Imperva in a research note on Thursday, June 2nd. Oppenheimer Holdings Inc. reiterated a “buy” rating and set a $60.00 price target on shares of Imperva in a research note on Tuesday, June 21st. Nomura reiterated a “buy” rating and set a $60.00 price target on shares of Imperva in a research note on Tuesday, June 21st. BTIG Research reiterated a “buy” rating and set a $55.00 price target on shares of Imperva in a research note on Tuesday, June 21st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Imperva in a research note on Tuesday, June 21st. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have assigned a buy rating to the company. Imperva presently has a consensus rating of “Buy” and a consensus target price of $54.05.

In related news, major shareholder Shlomo Kramer sold 75,000 shares of the stock in a transaction that occurred on Thursday, June 23rd. The stock was sold at an average price of $45.12, for a total transaction of $3,384,000.00. Following the completion of the transaction, the insider now directly owns 1,304,521 shares of the company’s stock, valued at $58,859,987.52. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Mark E. Kraynak sold 2,614 shares of the stock in a transaction that occurred on Tuesday, August 16th. The shares were sold at an average price of $47.73, for a total value of $124,766.22. Following the transaction, the senior vice president now directly owns 3,552 shares of the company’s stock, valued at $169,536.96. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company operates in the segment of development, marketing, sales, service and support of cyber-security solutions that protect business critical data and applications whether in the cloud or on premises.

5 Day Chart for NYSE:IMPV

Want to see what other hedge funds are holding IMPV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imperva Inc. (NYSE:IMPV).

Receive News & Ratings for Imperva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.